Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
CAMBRIDGE, Mass., Nov. 08, 2016 -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, with or without aura, announced today it will provide a corporate overview at the Stifel 2016 Healthcare Conference, being held on November 15-16 in New York City.
| Stifel 2016 Healthcare Conference | ||
| Date: | Tuesday, November 15 | |
| Time: | 2:15pm Eastern Time | |
| Location: | The Lotte New York Palace Hotel, Holmes I Room | |
| Webcast: | http://wsw.com/webcast/stifel5/clcd | |
About CoLucid Pharmaceuticals, Inc.
CoLucid is developing lasmiditan oral tablets for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.
CONTACT Thomas Mathers Chief Executive Officer CoLucid Pharmaceuticals, Inc. (857) 285-6494 Hans Vitzthum Managing Director LifeSci Advisors, LLC. (212) 915-2568
